- Name: Jiang Yang
- Title: Full Professor
- Email: yangjiang@sysucc.org.cn
- Phone: +86-020-31336609
Dr. Jiang Yang(ORCID:0000-0001-5934-1537) is a group leader of Department of Experimental Research. He graduated in Life Sciences with aB.S. from Zhejiang University,anM.S. from University of Leeds,and aPh.D.fromUniversity of Wisconsin-Madison in 2013. After postdoctoral research in Chemistry at Stanford University and in Radiologyat Memorial Sloan Kettering Cancer Center, he joined the Sun Yat-sen University Cancer Center in 2019 as a PI. His primary researchfocus is on multimodal imaging and theranostics ofvarious diseases, includingcancer. His academic excellence has been recognized through prestigious awards, including the NSF Scholarship,theLouis and Elsa Thomsen Wisconsin Distinguished Graduate Fellowship,theHjalmar D. and Janet W Bruhn Graduate Fellowship, the ASABE Outstanding Graduate Student Award of the Year, andChina’s top 10 Emerging Tech Figures.Dr. Yang has presidedover multiple NSFC grants,aSignificant New Drug Development (SNDD) grant, Guangdong provincial grants, andaShanghai Municipal Bureau grant, andhasparticipated in oneNationalKeyResearch andDevelopment Program. With over80 peer-reviewed publications in top-tier journals, including Science,Nature Biomedical Engineering,Journal of Clinical Investigation, Advanced Materials,ACS Nano,andBiomaterials, etc.,his work has garnered more than 11,000 citations (h-index: 38). Several publications have been featured on journal covers, highlighted as articles of the week, and designated as ESI Highly Cited Papers. Dr. Yang’s grouphas delivered60+ presentations at premier conferences in imaging and chemistry, including WMIC, EMIM, ACS, and SPIE, withseveral studies selected as WMIC Highlighted Lectures (top 5-scoring abstracts) and one study as a 2025 WMIC Young Investigator Award Finalist. Dr. Yang holds 5 granted US/PCT patents and 9 Chinese invention patent applications (5 granted),of which severalhave been licensed to biotech companies. He serves inaneditorial capacity forInternational Journal of Nanomedicine(consulting editor) and as a young editorial board member forJournal of Intelligent Medicine,Biomedical Technology, Exploration, andView. He successfully led an FDA Phase IIb clinical trial(PLANTCOAT-IIb)for a novel therapeutic agent that is currently in phase III (PLANTCOAT-III).
1. Multimodal imaging and theranostic molecular probes.
2. Image-guidedcancer interventions.
3. High-sensitivity in vitroassays forcancer and autoimmune disease diagnosis.
4. Synthesis andbiologicalmechanisms of nanoparticles.
Department of Radiology,Memorial Sloan Kettering Cancer Center, Research Fellow/Research Scholar/Visiting Investigator, 2015-2019
Department of Chemistry, Stanford University, Postdoc, 2013-2015
College of Agricultural and Life Sciences, University of Wisconsin-Madison, Ph.D., 2007-2013
Faculty of Biological Sciences,University of Leeds, M.S., 2006-2007
College of Life Sciences, Zhejiang University, B.S., 2003-2006
1. Xing W.#, Zhou Y.#, Haedicke K., Wang C., Vázquez-Prada K. X., Wu H., Lin Z., Andreou C., Zhang Q., Shang K., Hu R., Kircher M., Ye X.*, Grimm J.*, Yang J.* (2026). Label-free streamlined photoacoustic image-guidance facilitates NIR-II photoablation in models of melanoma lung metastases. Journal of Clinical Investigation, In Press
3. Yang J.* (2026). When ties unravel. Science, 392 (6796), 434
4. You Y., Lin Z., Chen J., Liu J., Luo Y., Ye X.*, Yang J.* (2025). High-sensitivity cell-based plasmonic biolayer interferometry with a two-tiered enhancement for clinical autoimmunity surveillance of pemphigus vulgaris. ACS Nano, 19, 21, 19552–19566 (Cover)
5. Li G., Yi L., Zhang S., Song Q., Liang M., Guan Z., Zhang Y., Zhuang Y., Hou B., Wang X., Wu X., Yin P., Klyuyev D., Yang J.*, Hu B.*, Tian J.* (2025). Concentration indicator kit based on dandelion propagation-inspired SERS strategy. Advanced Materials, 14 (2), 2502162
6. Pang J.#, Chen X.#, Lin Z., Yao S., Wang W., Wu H., Xing W.*, Yang J.* (2025). Inhalable pH-responsive charge-reversal polymer-small interfering RNA polyplexes for directed gene therapy of anaplastic lymphoma kinase fusion-positive lung cancer. Journal of Controlled Release, 381, 113644
7. Liu D.#, Cao F.#, Xu Z.#, Zhao C., Liu Z., Pang J., Liu Z.X., Moghiseh M., Butler A., Liang S., Fan W.*, Yang J.* (2024). Selective organ-targeting hafnium oxide nanoparticles with multienzyme-mimetic activities attenuate radiation-induced tissue damage. Advanced Materials, 36 (19), 2308098 (Back Cover)
8. Lin Z., Liu M., Xing W., Wang F., Zhang H., Wei X., Schmitthenner H., Xie X., Xia X.*, Yang J.* (2023). A near-infrared fluorescence-enhancing plasmonic biosensing microarray identifies soluble PD-L1 and ICAM-1 as predictive checkpoint biomarkers for cancer immunotherapy. Biosensors and Bioelectronics 240, 115633
9. Zhao C.#, Liu Z.#, Chang C-C., Chen Y-C., Zhang Q., Zhang X-D., Andreou C., Pang J., Liu Z-X.*, Wang D-Y.*, Kircher M.F., Yang J.* (2023). Near-infrared phototheranostic iron pyrite nanocrystals simultaneously induce dual cell death pathways via enhanced Fenton reactions in triple-negative breast cancer. ACS Nano 17 (5), 4261-4278. (Cover)
10. Yang J., Wang T., Zhao L., Rajasekhar V.K., Joshi S., Hsu H., Zhang H., Huang R., Hendrickson R.C., Miele M.M., Pei W., Brendel M.B., Healey J.H., Chiosis G., Kircher M.F.* (2020). Gold-alpha-lactalbumin nanoprobes for the imaging and therapy of breast cancer. Nature Biomedical Engineering 4 (7), 686-703 (Front Cover)
